Advertisement
RayzeBio Inc. Common Stoc... (RYZB)
NASDAQ: RYZB
· Real-Time Price · USD
62.49
0.01 (0.02%)
At close: Feb 23, 2024, 9:00 PM
Company Description
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer.
The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs).
It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC.
The company was incorporated in 2020 and is based in San Diego, California.
RayzeBio Inc. Common Stock
| Country | United States |
| IPO Date | Sep 15, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Dr. Kenneth Song M.D. |
Advertisement
Contact Details
Address: No Address available No city data available, Delaware United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | RYZB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001825367 |
| CUSIP Number | 75525N107 |
| ISIN Number | US75525N1072 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kenneth Song M.D. | President, Chief Executive Officer & Director |
| Arvind Kush | Chief Financial Officer |
| Abhi Bhat Ph.D. | Senior Vice President of Chemistry & Head of Discovery |
| Aron Marc Knickerbocker | Co-Founder |
| Dr. Gary G. Li Ph.D. | Senior Vice President of Biology & Translational Medicine |
| Dr. Nicholas D. Smith Ph.D. | Senior Vice President of Chemistry Innovation |
| Dr. Susan Moran M.D. | Chief Medical Officer |
| Eric Bischoff | Senior Vice President of Development & Operations |
| Jeff Woodley | General Counsel |
| Kimberly Ma M.S. | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 07, 2024 | 15-12G | Filing |
| Feb 28, 2024 | 4 | Filing |
| Feb 28, 2024 | 4 | Filing |
| Feb 28, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |